H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod

Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts.

Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the most promising stocks.

On February 23, 2026, H.C. Wainwright increased the price target for ARMP from $9.00 to $15.00 and kept a Buy rating on the shares. The modification comes after the FDA designated AP-SA02 as a Qualified Infectious Disease Product, providing extra regulatory support as the business gets ready for its Phase 3 superiority research, which is set for the second half of 2026.

Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) declared on February 23 that its intravenous Staphylococcus aureus multi-phage candidate, AP-SA02, has been given Qualified Infectious Disease Product (QIDP) classification by the U.S. FDA. Its usage as an adjuvant treatment for complex bacteremia brought on by both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) S. aureus is covered by the designation. In the second half of 2026, the company plans to place AP-SA02 into a Phase 3 superiority trial for complex bloodstream infections caused by S. aureus.

Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is a clinical-stage biotech company developing precision bacteriophage-based therapies to treat antibiotic-resistant and hard-to-treat bacterial infections, advancing a pipeline of pathogen-specific phage candidates from discovery through clinical trials.

While we acknowledge the potential of ARMP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the

Disclosure: None.